腾博会官网·[中国]-诚信为本,专业服务!

The company adheres to the vision of "focusing on innovation, serving patients and becoming a leading pharmaceutical enterprise in the world" ,and has continuously invested heavily in building scientific and technological innovation ability for many years. The R & D investment has reached or exceeded the total income by 16% for many years, far exceeding other domestic peers.

At present, there are many research centers in Beijing, Nanjing, Lianyungang, Qingdao and Shanghai. The total construction area of the R & D center exceeds 170,000 square meters. The total number of experienced high-level R & D personnel has rapidly increased from 500 in 2013 to more than 2700. Dozens of research platforms and mature R & D technology platforms have been built, widely connected and in-depth cooperation with famous research institutions, universities and hospitals at home and abroad.

CTTQ, a member enterprise, was rated as "the top three Chinese chemical drug R&D strength" at the China Pharmaceutical R&D Innovation Summit in 2017-2021 for five consecutive years; The scientific research project of the establishment and application of key emulsification technology system in new drug preparations of Beijing Tide Pharmaceutical Co., Ltd. won the "Second Prize of the National Science and Technology Progress Award".